- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Insulin Lispro, regular human insulin, recombinant human hyaluronidase PH20, Insulin glargine
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 8
- States / cities
- Aurora, Colorado • Miami, Florida • Detroit, Michigan + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1153–1176
of 7,459
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neuroblastoma
- Interventions
- 131I-MIBG, Dinutuximab, Vorinostat, Sargramostim, Potassium Iodide
- Radiation · Drug
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more
- Conditions
- Metabolic Acidosis, Kidney Transplant; Complications, Vascular Diseases
- Interventions
- Sodium bicarbonate, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Immunization Rates
- Interventions
- Collaborative Pop-Based R/R: Phone/Mail Group, Collaborative Pop-Based R/R: Mail-Only Group, Practice-based Recall
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 19 Months to 5 Years
- Enrollment
- 68,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Denver, Colorado
- Conditions
- Angina Pectoris
- Interventions
- pVGI.1(VEGF2)
- Genetic
- Lead sponsor
- Corautus Genetics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 27 more
- Conditions
- Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypercholesterolemia, Cardiovascular Diseases, Pharmacists, Placebo Effect
- Interventions
- Virtual Statin Management (VSM)
- Other
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 898 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Advanced Solid Tumors
- Interventions
- ARRY-382, Pembrolizumab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 30
- States / cities
- Los Angeles, California • Santa Monica, California • Aurora, Colorado + 12 more
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
- Interventions
- Quality-of-Life Assessment, Questionnaire Administration
- Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 347
- States / cities
- Fairbanks, Alaska • Kingman, Arizona • Phoenix, Arizona + 215 more
- Conditions
- Atrial Fibrillation, Paroxysmal AF
- Interventions
- Catheter Ablation
- Device
- Lead sponsor
- Biosense Webster, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Santa Barbara, California + 23 more
- Conditions
- Hemostasis
- Interventions
- QuikClot Control+
- Device
- Lead sponsor
- Z-Medica
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Pocatello, Idaho + 4 more
- Conditions
- Hemophilia A
- Interventions
- BIIB031 (rFVIIIFc), FVIII (PK subgroup only)
- Drug
- Lead sponsor
- Bioverativ Therapeutics Inc.
- Industry
- Eligibility
- Up to 11 Years · Male only
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 9 more
- Conditions
- Childhood Medulloblastoma
- Interventions
- Audiometric Test, Auditory Brainstem Response, Biospecimen Collection, Cisplatin, Cyclophosphamide, Lomustine, Magnetic Resonance Imaging, Quality-of-Life Assessment, Radiation Therapy, Sodium Thiosulfate, Survey Administration, Vincristine
- Procedure · Drug · Other + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 4 Years to 21 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 106
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 92 more
- Conditions
- Non-alcoholic Fatty Liver Disease in Women With PCOS
- Interventions
- Saroglitazar Magnesium 4 mg Tablet, Placebo
- Drug
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 13
- States / cities
- Chandler, Arizona • Panorama City, California • San Francisco, California + 9 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exenatide Once Weekly, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 14,752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 139
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 124 more
- Conditions
- HIV Infections
- Interventions
- Tetanus toxoid, Hepatitis A Vaccine (Inactivated)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years to 24 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Alhambra, California • Long Beach, California + 18 more
- Conditions
- Juvenile Spondyloarthritis
- Interventions
- Standard TNFi Therapy, TNFi fixed longer dosing intervals, Stop TNFi treatment
- Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 8 Years to 21 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
- Conditions
- Mild Cognitive Impairment
- Interventions
- Advance Care Planning Group Visits
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Aurora, Colorado
- Conditions
- Malignant Melanoma
- Interventions
- Atezolizumab, Cobimetinib, Vemurafenib
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Aurora, Colorado • Sarasota, Florida + 3 more
- Conditions
- HIV
- Interventions
- zidovudine 300mg and lamivudine 150mg as Combivir
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Cystic Fibrosis
- Interventions
- Discontinuation of dornase alfa (Dnase), Continuation of dornase alfa (Dnase)
- Other
- Lead sponsor
- Nicole Hamblett
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more
- Conditions
- Bladder Cancer
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- COPD, Pulmonary Hypertension, Right Ventricular Dysfunction, Exercise, Exercise Training
- Interventions
- Exercise
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Bisphosphonate, Setrusumab
- Drug · Biological
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 2 Years to 6 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 10 more
- Conditions
- Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation, Metastatic Solid Tumor, Advanced Solid Tumor
- Interventions
- TPX-0046
- Drug
- Lead sponsor
- Turning Point Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 20
- States / cities
- La Jolla, California • Orange, California • Aurora, Colorado + 15 more